Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant serplulimab plus chemotherapy for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2400093116Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Chinese PLA General Hospital. Primary endpoint: Pathological complete remission rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400093116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093116.